Calcitonin gene-related peptide (CGRP) monoclonal antibodies, or CGRP antagonists, are one of the newer treatment options for the prevention of migraine.In recent years, pharmaceutical companies have tested drugs in this class to dramatically reduce the frequency of migraine episodes for people with chronic migraine. Calcitonin gene-related peptide (CGRP) monoclonal antibodies work by bringing down levels of CGRP, which transmits pain. Monoclonal antibodies are a part of a drug class called biologics. These medications are taken by injection. The dosage and frequency of injection may vary depending on symptoms. Gepants block the CGRP receptor, and by doing this blocks the migraine mechanisms. So can gepants can be called “CGRP antagonists” or “blockers”. The most unique thing about gepants is that they can be used for the treatment of the attacks (Ubrogepant, Rimegepant), AND/OR for prevention (Atogepant, Rimegepant). That’s a new reality for migraine therapy. Up until now, acute treatments were taken as needed for the attack, and preventives were taken every day (for pills) to decrease the frequency of attacks. As a rule, acute medications were limited to 10-15 days per month due to the risk of medication overuse headache. With gepants, these concepts do not apply.